---
title: Randomised, bioequivalence clinical trial of rasagiline 1 mg capsules vs rasagiline 1 mg tablets, after a single oral dose administration to healthy volunteers under fasting conditions in crossover replicated design.
euct_id: 2024-512311-41-00
phase: Phase 2
status: Completed
sponsor: Laboratorios Alter S.A.
canonical_url: "https://parkinsonspathways.com/trials/eu/2024-512311-41-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2024-512311-41-00"
ctis_last_updated: "2025-06-25T03:36:32.562930694"
source: EU Clinical Trials Information System (CTIS)
---
# Randomised, bioequivalence clinical trial of rasagiline 1 mg capsules vs rasagiline 1 mg tablets, after a single oral dose administration to healthy volunteers under fasting conditions in crossover replicated design.

**EU CT Number:** [2024-512311-41-00](https://euclinicaltrials.eu/ctis-public/view/2024-512311-41-00)

## Key Facts

- **Phase:** Phase 2
- **Status:** Completed
- **Sponsor:** Laboratorios Alter S.A.
- **Start Date:** 2024-05-01
- **Completion Date:** 2024-05-31
- **Conditions:** Parkinson´s disease

## Member States

Trial is authorized in 1 member state: Spain.

## Sites (1)

- Hospital Universitario De La Princesa, Madrid, Spain

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Maximum age:** 64 Years
- **Sex:** ALL

```
Condition: Parkinson´s disease
Age groups: adults 18-64
Sex: male, female
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2024-512311-41-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2024-512311-41-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2024-512311-41-00*